Skip to main content
Clinical Trials/NCT03235063
NCT03235063
Completed
Not Applicable

Registry of Pregnancy Follow-up in Patients With Dilated Cardiomyopathy

Nantes University Hospital15 sites in 1 country42 target enrollmentJanuary 2, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Dilated Cardiomyopathy
Sponsor
Nantes University Hospital
Enrollment
42
Locations
15
Primary Endpoint
evaluate clinical characteristics
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Increasing cases of women with dilated cardiomyopathy with a project of pregnancy are observed. However there is few knowledge and publications about cardiac diseases in pregnant women. Moreover the majority of medical articles deal with women with congenital heart diseases, valvular pathologies or peripartum cardiomyopathies, and few data are available in literature about women with dilated cardiomyopathy diagnosed before or during the first months of the pregnancy.

Cardiologist and obstetrician advices are considerably limited when patients with dilated cardiomyopathy have a pregnancy project. Knowledges and know-how are currently based on limited personal experiment or on few clinical cases descriptions.

Pregnancy represents a high-risk situation for patients with dilated cardiomyopathy. Creation of a cohort of pregnant women with dilated cardiomyopathy collecting specific data will allow to have a better overview and to appreciate possibilities of a pregnancy project, evolution risks and modalities for medical attention and to improve follow-up and advices delivered to these patients.

Detailed Description

This study is a national (20 centres) retrospective (10 years) and prospective registry of pregnant women with dilated cardiomyopathy. As this study is observational, medical attention of the enrolled patients will not be modified. No specific visit is planned for the study. Before the enrolment of the patient, the investigator provides the subject with clear and precise information about the protocol and requests her for written informed consent. The French ethical committee gave the investigators the possibility to include women in the registry if the investigators are unable to inform her (deceased women, no follow-up). The main objective of the study is to evaluate clinical characteristics and study maternal and neonatal evolution and complications during pregnancy using analysis of the morbi-mortality and clinical and para clinical criteria. The following data will be compiled in a case report form (e-CRF): * Risk factors, cardiac history * BNP or NTproBNP value, echocardiographic data (LVEF and LV diameter) * Medical treatment before and during the pregnancy * complications; occurrences during the pregnancy * Modalities of medical attention during delivery: mother/child Patient's data are coded, and therefore anonymous, by using the inclusion number and initials of the patient (first letter of name and first letter of surname (ex: 01-X_X). In this prospective and retrospective, multi-centre, clinical study, all patients enrolled in the cohort will be included in the statistical analysis. As an observational non-randomized single arm evaluation, the statistical analyses will be descriptive. A minimum of 100 patients will be enrolled.

Registry
clinicaltrials.gov
Start Date
January 2, 2013
End Date
June 30, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients over the age of majority
  • Followed-up for non-ischemic left heart failure, diagnosed before or during the pregnancy or with peripartum history, with a left ventricular ejection fraction \< 50% and/or a left ventricle diameter \> 27 mm/m2
  • In New York Heart Association (NYHA) class 1 to 4
  • Pregnant or with pregnancy history
  • Patients with left ventricular non-compaction, valvular cardiomyopathy operated or not can also be enrolled

Exclusion Criteria

  • Refusal for participation
  • Ischemic, hypertrophic, restrictive and congenital cardiomyopathies

Outcomes

Primary Outcomes

evaluate clinical characteristics

Time Frame: Jan 2018

Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.

study maternal

Time Frame: Jan 2018

Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.

neonatal evolution

Time Frame: Jan 2018

Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.

complications during pregnancy

Time Frame: Jan 2018

Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.

Secondary Outcomes

  • quarterly blood rate of Brain Natriuretic Peptide (BNP)(Jan 2018)
  • quarterly blood rate of N-Terminal pro-Brain Natriuretic Peptide (NTproBNP)(Jan 2018)
  • quarterly evolution of left ventricular ejection fraction(Jan 2018)
  • left ventricular ejection diameter(Jan 2018)
  • modalities of medical attention during delivery(Jan 2018)
  • modalities of mother medical attention during peripartum(Jan 2018)
  • treatment before and during the pregnancy(Jan 2018)
  • modalities of new-born medical attention(Jan 2018)

Study Sites (15)

Loading locations...

Similar Trials